Table 2.

Response to treatment

Response	Total cohort	Neratinib monotherapy	Neratinib with capecitabine
	n (%)	n (%)	n (%)
SD	14 (19)	4 (15)	10 (22)
PR	26 (36)	7 (26)	19 (42)
CR	3 (4)	0 (0)	3 (7)
PD	18 (25)	7 (26)	11 (24)
Non evaluable ψ	11 (15)	9 (33)	2 (4)
ORR	29 (40)	7 (26)	21(47)
CBR	38 (64)	7 (26)	31 (69)

Defined in the method section

SD stable disease, PR partial response, CR complete response, PD progressive disease, ORR objective response rate, CBR clinical benefit rate

Response radiologically as per reporting radiologist

ψ2 patients not evaluable radiologically due to cutaneous only disease; the other 9 patients progressed clinically before radiological assessment undertaken